These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10073892)

  • 1. 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans.
    Hegadoren KM; Baker GB; Bourin M
    Neurosci Biobehav Rev; 1999 Mar; 23(4):539-53. PubMed ID: 10073892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adam and Eve make love. Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, "Eve") and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain.
    Tucker G
    Hum Exp Toxicol; 1996 May; 15(5):455-7. PubMed ID: 8735473
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of the enantiomers of 3,4-methylenedioxy-N-ethylamphetamine (MDE, "Eve") and its metabolite 3,4-methylenedioxyamphetamine (MDA) in rat brain.
    Hegadoren KM; Baker GB; Coutts RT
    J Pharmacol Toxicol Methods; 1995 Oct; 34(2):117-23. PubMed ID: 8563033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy").
    McKenna DJ; Peroutka SJ
    J Neurochem; 1990 Jan; 54(1):14-22. PubMed ID: 1967141
    [No Abstract]   [Full Text] [Related]  

  • 5. Structure-activity relationships of MDMA-like substances.
    Nichols DE; Oberlender R
    NIDA Res Monogr; 1989; 94():1-29. PubMed ID: 2575223
    [No Abstract]   [Full Text] [Related]  

  • 6. Second thoughts on 3,4-methylenedioxymethamphetamine (MDMA) neurotoxicity.
    Grob C; Bravo G; Walsh R
    Arch Gen Psychiatry; 1990 Mar; 47(3):288-9. PubMed ID: 1968330
    [No Abstract]   [Full Text] [Related]  

  • 7. [Entactogenic drugs "ecstasy" (MDMA), "eve" (MDE) and other ring-substituted methamphetamine derivatives. A new class of substances among illegal designer drugs?].
    Gouzoulis-Mayfrank E; Hermle L; Kovar KA; Sass H
    Nervenarzt; 1996 May; 67(5):369-80. PubMed ID: 9005345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity of MDA (3,4-methylenedioxyamphetamine) considered for relevance to hazards of MDMA (Ecstasy) abuse.
    Davis WM; Hatoum HT; Waters IW
    Alcohol Drug Res; 1987; 7(3):123-34. PubMed ID: 2881551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hallucinogens, amphetamines and entactogens].
    Vollenweider FX; Vollenweider-Scherpenhuyzen MF
    Ther Umsch; 2003 Jun; 60(6):323-8. PubMed ID: 12848067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reserpine does not prevent 3,4-methylenedioxymethamphetamine-induced neurotoxicity in the rat.
    Hekmatpanah CR; McKenna DJ; Peroutka SJ
    Neurosci Lett; 1989 Sep; 104(1-2):178-82. PubMed ID: 2573011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis.
    Maurer HH; Kraemer T; Springer D; Staack RF
    Ther Drug Monit; 2004 Apr; 26(2):127-31. PubMed ID: 15228152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.
    Ketabi-Kiyanvash N; Weiss J; Haefeli WE; Mikus G
    Addict Biol; 2003 Dec; 8(4):413-8. PubMed ID: 14690877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA).
    Freudenmann RW; Spitzer M
    CNS Drug Rev; 2004; 10(2):89-116. PubMed ID: 15179441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").
    McNamara R; Kerans A; O'Neill B; Harkin A
    Neuropharmacology; 2006 Jan; 50(1):69-80. PubMed ID: 16188283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans.
    Ricaurte GA; McCann UD
    Ann N Y Acad Sci; 1992 May; 648():371-82. PubMed ID: 1379014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay.
    Ensslin HK; Kovar KA; Maurer HH
    J Chromatogr B Biomed Appl; 1996 Aug; 683(2):189-97. PubMed ID: 8891915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans.
    Steele TD; McCann UD; Ricaurte GA
    Addiction; 1994 May; 89(5):539-51. PubMed ID: 7913850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats.
    Meyer A; Mayerhofer A; Kovar KA; Schmidt WJ
    Neurosci Lett; 2002 Sep; 330(3):280-4. PubMed ID: 12270646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study of the mechanism of MDMA ('ecstasy')-induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds.
    Colado MI; Green AR
    Br J Pharmacol; 1994 Jan; 111(1):131-6. PubMed ID: 7516800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug.
    Solowij N; Hall W; Lee N
    Br J Addict; 1992 Aug; 87(8):1161-72. PubMed ID: 1354992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.